Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011, Article ID 143547, 5 pages
http://dx.doi.org/10.4061/2011/143547
Review Article

Neurobiology of Depression and Anxiety in Parkinson's Disease

1Department of Neurology, Toho University Omori Medical Center, 6-11-1 Omorinishi, Otaku, Tokyo 143-8541, Japan
2Department of Neurology, Methodist Neurological Institute, 6565 Fannin Street, B05-039G, Houston, TX 77030, USA
3Department of Bioinformatics and Bioengineering, Methodist Hospital Research Institute, 6565 Fannin Street, R6-212, Houston, TX 77030, USA

Received 15 October 2010; Accepted 13 March 2011

Academic Editor: Irena Rektorova

Copyright © 2011 Osamu Kano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Parkinson, “An essay on the shaking palsy. 1817,” The Journal of Neuropsychiatry and Clinical Neurosciences, vol. 14, no. 2, pp. 223–236, 2002. View at Google Scholar · View at Scopus
  2. A. Schrag, “Quality of life and depression in Parkinson's disease,” Journal of the Neurological Sciences, vol. 248, no. 1-2, pp. 151–157, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. S. S. O'Sullivan, D. R. Williams, D. A. Gallagher, L. A. Massey, L. Silveira-Moriyama, and A. J. Lees, “Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study,” Movement Disorders, vol. 23, no. 1, pp. 101–106, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. G. W. Ross, R. D. Abbott, H. Petrovitch et al., “Association of coffee and caffeine intake with the risk of Parkinson disease,” Journal of the American Medical Association, vol. 283, no. 20, pp. 2674–2679, 2000. View at Google Scholar · View at Scopus
  5. L. M. Shulman, R. L. Taback, A. A. Rabinstein, and W. J. Weiner, “Non-recognition of depression and other non-motor symptoms in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 8, no. 3, pp. 193–197, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Martinez-Martin and J. Damian, “Parkinson disease: depression and anxiety in Parkinson disease,” Nature Reviews Neurology, vol. 6, no. 5, pp. 243–245, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. K. R. Chaudhuri, D. G. Healy, and A. H. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. K. R. Chaudhuri and Y. Naidu, “Early Parkinson's disease and non-motor issues,” Journal of Neurology, vol. 255, supplement 5, pp. 33–38, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. R. Savica, W. A. Rocca, and J. E. Ahlskog, “When does Parkinson disease start?” Archives of Neurology, vol. 67, no. 7, pp. 798–801, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. M. Shiba, J. H. Bower, D. M. Maraganore et al., “Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study,” Movement Disorders, vol. 15, no. 4, pp. 669–677, 2000. View at Publisher · View at Google Scholar
  11. M. G. Weisskopf, H. Chen, M. A. Schwarzschild, I. Kawachi, and A. Ascherio, “Prospective study of phobic anxiety and risk of Parkinson's disease,” Movement Disorders, vol. 18, no. 6, pp. 646–651, 2003. View at Publisher · View at Google Scholar · View at PubMed
  12. J. H. Bower, B. R. Grossardt, D. M. Maraganore et al., “Anxious personality predicts an increased risk of Parkinson's disease,” Movement Disorders, vol. 25, no. 13, pp. 2105–2113, 2010. View at Publisher · View at Google Scholar · View at PubMed
  13. A. G. Schuurman, M. Van den Akker, K. T. Ensinck et al., “Increased risk of Parkinson's disease after depression: a retrospective cohort study,” Neurology, vol. 58, no. 10, pp. 1501–1504, 2002. View at Google Scholar
  14. A. Alonso, L. A. Rodríguez, G. Logroscino, and M. A. Hernán, “Use of antidepressants and the risk of Parkinson's disease: a prospective study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 6, pp. 671–674, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. E. L. Jacob, N. M. Gatto, A. Thompson, Y. Bordelon, and B. Ritz, “Occurrence of depression and anxiety prior to Parkinson's disease,” Parkinsonism and Related Disorders, vol. 16, no. 9, pp. 576–581, 2010. View at Publisher · View at Google Scholar · View at PubMed
  16. G. M. Pontone, J. R. Williams, K. E. Anderson et al., “Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease,” Movement Disorders, vol. 24, no. 9, pp. 1333–1338, 2009. View at Publisher · View at Google Scholar · View at PubMed
  17. D. Aarsland, L. Marsh, and A. Schrag, “Neuropsychiatric symptoms in Parkinson's disease,” Movement Disorders, vol. 24, no. 15, pp. 2175–2186, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. A. M. Kuopio, R. J. Marttila, H. Helenius, M. Toivonen, and U. K. Rinne, “The quality of life in Parkinson's disease,” Movement Disorders, vol. 15, no. 2, pp. 216–223, 2000. View at Publisher · View at Google Scholar
  19. J. L. Cummings and D. L. Masterman, “Depression in patients with Parkinson's disease,” International Journal of Geriatric Psychiatry, vol. 14, no. 9, pp. 711–718, 1999. View at Publisher · View at Google Scholar
  20. A. T. Beekman, J. R. Copeland, and M. J. Prince, “Review of community prevalence of depression in later life,” British Journal of Psychiatry, vol. 174, pp. 307–311, 1999. View at Google Scholar
  21. D. J. Burn, “Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease,” Movement Disorders, vol. 17, no. 3, pp. 445–454, 2002. View at Publisher · View at Google Scholar · View at PubMed
  22. P. Remy, M. Doder, A. Lees, N. Turjanski, and D. Brooks, “Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system,” Brain, vol. 128, no. 6, pp. 1314–1322, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. M. Menza, R. D. Dobkin, H. Marin et al., “A controlled trial of antidepressants in patients with Parkinson disease and depression,” Neurology, vol. 72, no. 10, pp. 886–892, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. D. Weintraub, S. Mavandadi, E. Mamikonyan et al., “Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease,” Neurology, vol. 75, no. 5, pp. 448–455, 2010. View at Publisher · View at Google Scholar · View at PubMed
  25. I. Rektorova, I. Rektor, M. Bares et al., “Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study,” European Journal of Neurology, vol. 10, no. 4, pp. 399–406, 2003. View at Publisher · View at Google Scholar
  26. O. Kano, K. Ikeda, T. Kiyozuka et al., “Beneficial effect of pramipexole for motor function and depression in Parkinson's disease,” Neuropsychiatric Disease and Treatment, vol. 4, no. 4, pp. 707–710, 2008. View at Google Scholar
  27. A. Roy, D. Pickar, M. Linnoila, A. R. Doran, P. Ninan, and S. M. Paul, “Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia,” Psychiatry Research, vol. 15, no. 4, pp. 281–292, 1985. View at Publisher · View at Google Scholar
  28. G. Lambert, M. Johansson, H. Agren, and P. Friberg, “Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders,” Archives of General Psychiatry, vol. 57, no. 8, pp. 787–793, 2000. View at Google Scholar
  29. I. Rektorova, M. Balaz, J. Svatova et al., “Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study,” Clinical Neuropharmacology, vol. 31, no. 5, pp. 261–266, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. R. Pahwa, M. A. Stacy, S. A. Factor et al., “Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease,” Neurology, vol. 68, no. 14, pp. 1108–1115, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. K. C. Pearson, “Mental disorders from low-dose bromocriptine,” New England Journal of Medicine, vol. 305, no. 3, p. 173, 1981. View at Google Scholar · View at Scopus
  32. P. Bxarone, W. Poewe, S. Albrecht et al., “Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial,” The Lancet Neurology, vol. 9, no. 6, pp. 573–580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Barone, L. Scarzella, R. Marconi et al., “Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study,” Journal of Neurology, vol. 253, no. 5, pp. 601–607, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. F. J. Vajda and C. Solinas, “Current approaches to management of depression in Parkinson's disease,” Journal of Clinical Neuroscience, vol. 12, no. 7, pp. 739–743, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. N. N. Dissanayaka, A. Sellbach, S. Matheson et al., “Anxiety disorders in Parkinson's disease: prevalence and risk factors,” Movement Disorders, vol. 25, no. 7, pp. 838–845, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. J. Mathew, J. D. Coplan, and J. M. Gorman, “Neurobiological mechanisms of social anxiety disorder,” American Journal of Psychiatry, vol. 158, no. 10, pp. 1558–1567, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. D. J. Nutt, C. J. Bell, and A. L. Malizia, “Brain mechanisms of social anxiety disorder,” Journal of Clinical Psychiatry, vol. 59, supplement 17, pp. 4–11, 1998. View at Google Scholar · View at Scopus
  38. L. Negre-Pages, H. Grandjean, M. Lapeyre-Mestre et al., “Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPAMiP study,” Movement Disorders, vol. 25, no. 2, pp. 157–166, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus